Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg/ml - solution for injection - 2,5 mg/ml - bortezomib mannitol boronic ester - bortezomib

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 2.5mg (as a mannitol boronic ester) - powder for injection - 2.5 mg - active: bortezomib 2.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 2.5mg (as a mannitol boronic ester) - powder for injection - 2.5 mg - active: bortezomib 2.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - bortezomib 3.5mg (as mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as mannitol boronic ester) excipient: mannitol - - in combination with melphalan and prednisone, indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. - as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - bortezomib 3.5mg (as mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as mannitol boronic ester) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - bortezomib

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents